Stephanie Gaillard | Scholars@Duke

Stephanie Gaillard
Adjunct Assistant Professor in the Department of Medicine

Dr. Stéphanie Gaillard is an Assistant Professor in Medical Oncology at the Duke Cancer Institute. Dr. Gaillard is board certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology. At Duke, she focuses on treating patients with gynecologic malignancies and conducts basic science and clinical research. Dr. Gaillard’s laboratory research focuses on elucidating the biology of ovarian cancer, especially metabolic changes in the development of ovarian tumors, and mechanisms of resistance to chemotherapy. Her clinical research interests center on the development of novel therapeutic strategies for the treatment of ovarian cancer through early phase clinical trials. In addition to the Ovarian Cancer Research Fund Liz Tilberis Grant, Dr. Gaillard has received a Department of Defense Breast Cancer Research Program pre-doctoral research award and a Conquer Cancer Foundation Young Investigator Award.

Current Appointments & Affiliations

Adjunct Assistant Professor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2017

Contact Information

2000B Burdock Rd, Baltimore, MD 21209
DUMC 3079, Durham, NC 27710
stephanie.gaillard@duke.edu (919) 423-1363

Background
Education, Training, & Certifications
- Medical Oncology Fellowship, Johns Hopkins University School of Medicine 2009 - 2012
- Internal Medicine Internship and Residency, Johns Hopkins University School of Medicine 2006 - 2009
Duke Appointment History
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2013 - 2018
- Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2012 - 2017
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2014 - 2012
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Najjar, O., A. Varghese, M. Shahi, R. Vang, S. Gaillard, T. Smith, and A. N. Fader. “Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report.” Gynecologic Oncology Reports 32 (May 1, 2020). https://doi.org/10.1016/j.gore.2020.100555.
    Full Text
  - Yen, Ting-Tai, Tian-Li Wang, Amanda N. Fader, Ie-Ming Shih, and Stéphanie Gaillard. “Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer.” Int J Gynecol Pathol 39, no. 1 (January 2020): 26–35. https://doi.org/10.1097/PGP.0000000000000585.
    Full Text Link to Item
  - Park, Youngran, M Herman Chui, Yohan Suryo Rahmanto, Zheng-Cheng Yu, Raghavendra A. Shamanna, Marina A. Bellani, Stephanie Gaillard, et al. “Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.” Clin Cancer Res 25, no. 18 (September 15, 2019): 5584–94. https://doi.org/10.1158/1078-0432.CCR-18-4222.
    Full Text Link to Item
  - Yu, Yu, Yohan Suryo Rahmanto, Yao-An Shen, Laura Ardighieri, Ben Davidson, Stephanie Gaillard, Ayse Ayhan, et al. “Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.” Ebiomedicine 47 (September 2019): 184–94. https://doi.org/10.1016/j.ebiom.2019.08.055.
    Full Text Link to Item
  - Gaillard, Stéphanie L., Marianna Zahurak, Anup Sharma, Jennifer N. Durham, Kim A. Reiss, Susan Sartorius-Mergenthaler, Melinda Downs, et al. “A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.” Cancer 125, no. 16 (August 15, 2019): 2837–45. https://doi.org/10.1002/cncr.32138.
    Full Text Link to Item
  - Gaillard, S. L., and R. L. Coleman. “Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?” Ann Oncol 30, no. 7 (July 1, 2019): 1025–28. https://doi.org/10.1093/annonc/mdz166.
    Full Text Link to Item
  - Gaillard, Stéphanie L., Kaitlyn J. Andreano, Laurie M. Gay, Meghan Steiner, Matthew S. Jorgensen, Brittany Anne Davidson, Laura J. Havrilesky, et al. “Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.” Gynecol Oncol 154, no. 1 (July 2019): 199–206. https://doi.org/10.1016/j.ygyno.2019.04.010.
    Full Text Link to Item
  - Asaka, Shiho, Ting-Tai Yen, Tian-Li Wang, Ie-Ming Shih, and Stephanie Gaillard. “T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.” Mod Pathol 32, no. 4 (April 2019): 576–84. https://doi.org/10.1038/s41379-018-0172-x.
    Full Text Link to Item
  - Tewari, K. S., I. Vergote, A. Oaknin, E. Alvarez, S. Gaillard, S. Lheureux, D. Rischin, et al. “GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (November 1, 2018): ix86. https://doi.org/10.1093/annonc/mdy436.027.
    Full Text
  - Gaillard, S., A. Oaknin, I. L. Ray-Coquard, I. B. Vergote, G. Scambia, N. Colombo, S. A. Ghamande, et al. “Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (October 1, 2018): viii332. https://doi.org/10.1093/annonc/mdy285.
    Full Text
  - Yu, Yu, Yohan Suryo Rahmanto, Meng-Horng Lee, Pei-Hsun Wu, Jude M. Phillip, Chuan-Hsiang Huang, Michele I. Vitolo, et al. “Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway.” Oncogene 37, no. 28 (July 2018): 3778–89. https://doi.org/10.1038/s41388-018-0241-0.
    Full Text Link to Item
  - Hong, Julian C., Jonathan Foote, Gloria Broadwater, Julie A. Sosa, Stephanie Gaillard, Laura J. Havrilesky, and Junzo P. Chino. “Data-Derived Treatment Duration Goal for Cervical Cancer: Should 8 Weeks Remain the Target in the Era of Concurrent Chemoradiation?” Jco Clin Cancer Inform 1 (November 2017): 1–15. https://doi.org/10.1200/CCI.16.00072.
    Full Text Link to Item
  - Fader, Amanda N., Jennifer Bergstrom, Amelia Jernigan, Edward J. Tanner, Kara Long Roche, Rebecca L. Stone, Kimberly L. Levinson, et al. “Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?” Gynecol Oncol 147, no. 1 (October 2017): 85–91. https://doi.org/10.1016/j.ygyno.2017.07.127.
    Full Text Link to Item
  - Chan, John K., Wei Deng, Robert V. Higgins, Krishnansu S. Tewari, Albert J. Bonebrake, Michael Hicks, Stephanie Gaillard, et al. “A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.” Gynecol Oncol 146, no. 3 (September 2017): 554–59. https://doi.org/10.1016/j.ygyno.2017.05.033.
    Full Text Link to Item
  - Hong, Julian C., Jonathan Foote, Gloria Broadwater, Stéphanie Gaillard, Laura J. Havrilesky, and Junzo P. Chino. “Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.” Int J Gynecol Cancer 27, no. 4 (May 2017): 720–29. https://doi.org/10.1097/IGC.0000000000000926.
    Full Text Link to Item
  - Gaillard, Stéphanie L., Angeles A. Secord, and Bradley Monk. “The role of immune checkpoint inhibition in the treatment of ovarian cancer.” Gynecol Oncol Res Pract 3 (2016): 11. https://doi.org/10.1186/s40661-016-0033-6.
    Full Text Link to Item
  - Yu, Yu, Stephanie Gaillard, Jude M. Phillip, Tai-Chung Huang, Sneha M. Pinto, Nayara G. Tessarollo, Zhen Zhang, et al. “Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.” Cancer Cell 28, no. 1 (July 13, 2015): 82–96. https://doi.org/10.1016/j.ccell.2015.05.009.
    Full Text Link to Item
  - Havrilesky, Laura J., Angeles Alvarez Secord, Jessie A. Ehrisman, Andrew Berchuck, Fidel A. Valea, Paula S. Lee, Stephanie L. Gaillard, et al. “Patient preferences in advanced or recurrent ovarian cancer.” Cancer 120, no. 23 (December 1, 2014): 3651–59. https://doi.org/10.1002/cncr.28940.
    Full Text Link to Item
  - Martin, Lainie P., Michael Sill, Mark S. Shahin, Matthew Powell, Paul DiSilvestro, Lisa M. Landrum, Stephanie L. Gaillard, Michael J. Goodheart, James Hoffman, and Russell J. Schilder. “A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.” Gynecol Oncol 132, no. 3 (March 2014): 526–30. https://doi.org/10.1016/j.ygyno.2013.12.018.
    Full Text Link to Item
  - Gaillard, Stephanie, Jason B. Dinoso, Julia A. Marsh, Amy E. DeZern, Karen A. O’Connell, Adam M. Spivak, Karla Alwood, Christine M. Durand, Richard F. Ambinder, and Joel N. Blankson. “Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy.” J Clin Virol 51, no. 3 (July 2011): 195–98. https://doi.org/10.1016/j.jcv.2011.04.002.
    Full Text Link to Item
  - Gaillard, Stéphanie, and Vered Stearns. “Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.” Breast Cancer Res 13, no. 2 (March 14, 2011): 205. https://doi.org/10.1186/bcr2818.
    Full Text Link to Item
  - Gaillard, S., and D. Armstrong. “Intraperitoneal chemotherapy for advanced epithelial ovarian cancer: Many questions, much promise&.” Oncology 25, no. 2 (February 1, 2011).
  - Gaillard, S., and F. E. Wondisford. “Thyroid-Stimulating Hormone and Thyroid-Stimulating Hormone Receptor,” December 1, 2009, 81–101. https://doi.org/10.1016/B978-1-4160-4745-2.00007-9.
    Full Text
  - Grasfeder, Linda L., Stephanie Gaillard, Stephen R. Hammes, Olga Ilkayeva, Christopher B. Newgard, Richard B. Hochberg, Mary A. Dwyer, Ching-Yi Chang, and Donald P. McDonnell. “Fasting-induced hepatic production of DHEA is regulated by PGC-1alpha, ERRalpha, and HNF4alpha.” Mol Endocrinol 23, no. 8 (August 2009): 1171–82. https://doi.org/10.1210/me.2009-0024.
    Full Text Link to Item
  - Stein, Rebecca A., Stéphanie Gaillard, and Donald P. McDonnell. “Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells.” J Steroid Biochem Mol Biol 114, no. 1–2 (March 2009): 106–12. https://doi.org/10.1016/j.jsbmb.2009.02.010.
    Full Text Link to Item
  - Gaillard, Stéphanie, Mary A. Dwyer, and Donald P. McDonnell. “Definition of the molecular basis for estrogen receptor-related receptor-alpha-cofactor interactions.” Mol Endocrinol 21, no. 1 (January 2007): 62–76. https://doi.org/10.1210/me.2006-0179.
    Full Text Link to Item
  - Zhang, Yi, Ke Ma, Prabodh Sadana, Farhana Chowdhury, Stephanie Gaillard, Fang Wang, Donald P. McDonnell, Terry G. Unterman, Marshall B. Elam, and Edwards A. Park. “Estrogen-related receptors stimulate pyruvate dehydrogenase kinase isoform 4 gene expression.” J Biol Chem 281, no. 52 (December 29, 2006): 39897–906. https://doi.org/10.1074/jbc.M608657200.
    Full Text Link to Item
  - Gaillard, Stéphanie, Linda L. Grasfeder, Christiane L. Haeffele, Edward K. Lobenhofer, Tzu-Ming Chu, Russ Wolfinger, Dmitri Kazmin, et al. “Receptor-selective coactivators as tools to define the biology of specific receptor-coactivator pairs.” Mol Cell 24, no. 5 (December 8, 2006): 797–803. https://doi.org/10.1016/j.molcel.2006.10.012.
    Full Text Link to Item
  - Chao, Esther Y. H., Jon L. Collins, Stéphanie Gaillard, Aaron B. Miller, Liping Wang, Lisa A. Orband-Miller, Robert T. Nolte, Donald P. McDonnell, Timothy M. Willson, and William J. Zuercher. “Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.” Bioorg Med Chem Lett 16, no. 4 (February 15, 2006): 821–24. https://doi.org/10.1016/j.bmcl.2005.11.030.
    Full Text Link to Item
  - Safi, Rachid, Agnes Kovacic, Stéphanie Gaillard, Yoko Murata, Evan R. Simpson, Donald P. McDonnell, and Colin D. Clyne. “Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy.” Cancer Res 65, no. 24 (December 15, 2005): 11762–70. https://doi.org/10.1158/0008-5472.CAN-05-2792.
    Full Text Link to Item
  - Kovacs, Jeffrey J., Patrick J. M. Murphy, Stéphanie Gaillard, Xuan Zhao, June-Tai Wu, Christopher V. Nicchitta, Minoru Yoshida, David O. Toft, William B. Pratt, and Tso-Pang Yao. “HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.” Mol Cell 18, no. 5 (May 27, 2005): 601–7. https://doi.org/10.1016/j.molcel.2005.04.021.
    Full Text Link to Item
  - Zuercher, William J., Stéphanie Gaillard, Lisa A. Orband-Miller, Esther Y. H. Chao, Barry G. Shearer, David G. Jones, Aaron B. Miller, Jon L. Collins, Donald P. McDonnell, and Timothy M. Willson. “Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma.” J Med Chem 48, no. 9 (May 5, 2005): 3107–9. https://doi.org/10.1021/jm050161j.
    Full Text Link to Item
- Book Sections
  - Gaillard, S., G. L. Maxwell, A. K. Sood, and A. Berchuck. “Biology and genetics.” In Berek and Hacker’s Gynecologic Oncology: Sixth Edition, 2–38, 2014.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Publications

Academic Articles

Book Sections